Physician-scientist and ophthalmology drug development leader brings deep clinical and regulatory expertise to support Qlaris Bio’s late-stage pipeline DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies for glaucoma, today announced the appointment of Parisa Zamiri, M.D., Ph.D., to its board of directors. Dr. Zamiri’s appointment comes as Qlaris continues […]
News and EventsNews and Events
Qlaris Bio Appoints Fred Guerard, Pharm.D., as President and Chief Executive Officer
DEDHAM, Mass., March 10, 2026 – Qlaris Bio, Inc., (“Qlaris”), a clinical-stage biotechnology company developing first-in-class therapies for glaucoma, today announced the appointment of Fred Guerard, Pharm.D., as president and chief executive officer (CEO), effective March 1, 2026. He will also join the company’s Board of Directors. Dr. Guerard brings more than two decades of […]
Qlaris Bio Appoints Robert Warner to Board of Directors
Experienced life sciences executive brings strategic and leadership expertise to support Qlaris Bio’s next phase of growth DEDHAM, Mass.–(BUSINESS WIRE)–Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies for glaucoma, today announced the appointment of Robert Warner to its board of directors. Mr. Warner’s appointment comes at a key time for Qlaris […]
Qlaris Bio to present new clinical and preclinical data on QLS-111 at 2025 World Glaucoma Congress
QLS-111’s novel intraocular pressure-lowering mechanism targeting EVP to be highlighted in an oral presentation and two poster presentations DEDHAM, Mass. — June 23, 2025 — Qlaris Bio, Inc., a clinical‐stage biotechnology company dedicated to developing first‐in‐class therapies for glaucoma, today announced that new data from studies of its lead investigational compound QLS-111 will be presented […]
Qlaris Bio announces development of fixed-dose combination therapy with QLS-111 and latanoprost for the treatment of glaucoma
Combination therapy seeks to improve intraocular pressure lowering by pairing a novel EVP-targeting agent with prostaglandin analogue standard of care DEDHAM, Mass. — June 11, 2025 — Qlaris Bio, Inc., a clinical-stage biotechnology company, today announced that it is developing a novel preservative-free, fixed-dose combination (FDC) therapy that combines the company’s lead program, QLS-111, and […]
An Interview With Our Founders, Thurein Htoo and Dr. Barbara Wirostko, On The Apteryx and Osprey Clinical Studies
Interviewed by Carey Powers of Powers & Company at the Glaucoma 360 New Horizons Forum 2025.